Triple negative breast cancer: a new treatment authorized in France on November 1 – The HuffPost

Denis Balibouse / Reuters

CANCER – The Minister of Health, Olivier Véran, announced this Tuesday, October 5 that a promising new treatment against an aggressive form of breast cancer, known as “triple negative”, would be authorized and available in France from 1 November.

Against this cancer, “there is finally a promising treatment produced by an American laboratory, which is called the Trodelvy”, underlined Olivier Véran during the question-and-answer session in the Assembly, this month of pink October, breast cancer awareness month.

“France was the first European country to be able to benefit a few patients while waiting for production to increase; I can confirm that it will be authorized for early access and available in France from November 1, 2021 ”, continued the minister, speaking of“ good news ”.

Trodelvy is an antibody therapy combined with a chemotherapy, manufactured by the Gilead Laboratory.

9,000 people affected each year

A particularly aggressive form of the disease, triple negative breast cancer is the least common, but represents about 15% of cases, or 9,000 people each year.

In early September, the High Authority for Health (HAS) announced that patients with this cancer – on which current drugs do not work – could exceptionally receive this new treatment which is not yet authorized.

The HAS has granted an early access permit to Trodelvy for one year.

For its part, the Medicines Agency (ANSM) specified that Trodelvy was subject to “an accelerated marketing authorization assessment (AMM) by the European Medicines Agency (EMA) ”.

See also on The HuffPost: Pink October: This Breast Cancer Survivor Will Convince You To Learn Self-Palpation